Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
NCT ID NCT04940299
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combination is safe enough to allow more patients to benefit from powerful immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tocilizumab (a drug that calms the immune system) combined with ipilimumab and nivolumab (immunotherapy drugs that help the immune system attack cancer)
What this could lead to
If it works, this could make a powerful but harsh cancer treatment safer and more tolerable for more patients.
What could go wrong
This is a small, early-phase study with only 35 participants, so results may not apply to everyone. Adding tocilizumab could also reduce the immune system's cancer-fighting power.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.